Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat

M. Mian, D. Benetti, R. Aloisi, S. Rosini, R. Fantozzi, L. Savarino, S. Stea, M. E. Donati, G. Paganetto, A. Pizzoferrato

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective. This study was carried out to evaluate the effectiveness of two newly synthesized bisphosphonates (BPs) [Alendronate(4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP)) and Neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AHHexBP)], administered orally, in reducing experimentally induced bone loss. Methods. Unilateral sciatic nerve section was performed on the Sprague-Dawley rat to induce osteopenia in one of the hind limbs. Histomorphometric measurements of the tibial trabecular bone and femur ash content determinations were effected to assess the degree of osteopenia. For comparison Chlodronate (dichloromethylene-1-bisphosphonic acid (Cl 2MBP) was employed as the reference drug. Conclusions. The results of this investigation show that both BPs were significantly active in reducing the osteopenic process in the involved limb and were more active than Chlodronate.

Original languageEnglish
Pages (from-to)619-624
Number of pages6
JournalClinical and Experimental Rheumatology
Volume14
Issue number6
Publication statusPublished - Nov 1996

Fingerprint

Metabolic Bone Diseases
Diphosphonates
Extremities
Bone and Bones
Alendronate
Acids
Sciatic Nerve
Femur
Sprague Dawley Rats
Pharmaceutical Preparations
6-amino-1-hydroxyhexane-1,1-diphosphonate
Cancellous Bone
bone ash

Keywords

  • Ash
  • Bisphosphonates
  • Histomorphometry
  • Osteoporosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Mian, M., Benetti, D., Aloisi, R., Rosini, S., Fantozzi, R., Savarino, L., ... Pizzoferrato, A. (1996). Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat. Clinical and Experimental Rheumatology, 14(6), 619-624.

Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat. / Mian, M.; Benetti, D.; Aloisi, R.; Rosini, S.; Fantozzi, R.; Savarino, L.; Stea, S.; Donati, M. E.; Paganetto, G.; Pizzoferrato, A.

In: Clinical and Experimental Rheumatology, Vol. 14, No. 6, 11.1996, p. 619-624.

Research output: Contribution to journalArticle

Mian, M, Benetti, D, Aloisi, R, Rosini, S, Fantozzi, R, Savarino, L, Stea, S, Donati, ME, Paganetto, G & Pizzoferrato, A 1996, 'Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat', Clinical and Experimental Rheumatology, vol. 14, no. 6, pp. 619-624.
Mian M, Benetti D, Aloisi R, Rosini S, Fantozzi R, Savarino L et al. Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat. Clinical and Experimental Rheumatology. 1996 Nov;14(6):619-624.
Mian, M. ; Benetti, D. ; Aloisi, R. ; Rosini, S. ; Fantozzi, R. ; Savarino, L. ; Stea, S. ; Donati, M. E. ; Paganetto, G. ; Pizzoferrato, A. / Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat. In: Clinical and Experimental Rheumatology. 1996 ; Vol. 14, No. 6. pp. 619-624.
@article{4260112b71e246baa6301ccbd128a16b,
title = "Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat",
abstract = "Objective. This study was carried out to evaluate the effectiveness of two newly synthesized bisphosphonates (BPs) [Alendronate(4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP)) and Neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AHHexBP)], administered orally, in reducing experimentally induced bone loss. Methods. Unilateral sciatic nerve section was performed on the Sprague-Dawley rat to induce osteopenia in one of the hind limbs. Histomorphometric measurements of the tibial trabecular bone and femur ash content determinations were effected to assess the degree of osteopenia. For comparison Chlodronate (dichloromethylene-1-bisphosphonic acid (Cl 2MBP) was employed as the reference drug. Conclusions. The results of this investigation show that both BPs were significantly active in reducing the osteopenic process in the involved limb and were more active than Chlodronate.",
keywords = "Ash, Bisphosphonates, Histomorphometry, Osteoporosis",
author = "M. Mian and D. Benetti and R. Aloisi and S. Rosini and R. Fantozzi and L. Savarino and S. Stea and Donati, {M. E.} and G. Paganetto and A. Pizzoferrato",
year = "1996",
month = "11",
language = "English",
volume = "14",
pages = "619--624",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "6",

}

TY - JOUR

T1 - Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat

AU - Mian, M.

AU - Benetti, D.

AU - Aloisi, R.

AU - Rosini, S.

AU - Fantozzi, R.

AU - Savarino, L.

AU - Stea, S.

AU - Donati, M. E.

AU - Paganetto, G.

AU - Pizzoferrato, A.

PY - 1996/11

Y1 - 1996/11

N2 - Objective. This study was carried out to evaluate the effectiveness of two newly synthesized bisphosphonates (BPs) [Alendronate(4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP)) and Neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AHHexBP)], administered orally, in reducing experimentally induced bone loss. Methods. Unilateral sciatic nerve section was performed on the Sprague-Dawley rat to induce osteopenia in one of the hind limbs. Histomorphometric measurements of the tibial trabecular bone and femur ash content determinations were effected to assess the degree of osteopenia. For comparison Chlodronate (dichloromethylene-1-bisphosphonic acid (Cl 2MBP) was employed as the reference drug. Conclusions. The results of this investigation show that both BPs were significantly active in reducing the osteopenic process in the involved limb and were more active than Chlodronate.

AB - Objective. This study was carried out to evaluate the effectiveness of two newly synthesized bisphosphonates (BPs) [Alendronate(4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP)) and Neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AHHexBP)], administered orally, in reducing experimentally induced bone loss. Methods. Unilateral sciatic nerve section was performed on the Sprague-Dawley rat to induce osteopenia in one of the hind limbs. Histomorphometric measurements of the tibial trabecular bone and femur ash content determinations were effected to assess the degree of osteopenia. For comparison Chlodronate (dichloromethylene-1-bisphosphonic acid (Cl 2MBP) was employed as the reference drug. Conclusions. The results of this investigation show that both BPs were significantly active in reducing the osteopenic process in the involved limb and were more active than Chlodronate.

KW - Ash

KW - Bisphosphonates

KW - Histomorphometry

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=0030456169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030456169&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 619

EP - 624

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 6

ER -